Clinical Trials

Inclusion Criteria

• Male and female lung transplant recipients age >18 at the time of informed consent.
• Patients clinically meet indication for post-transplant lung biopsy or planned routine surveillance and have been scheduled for bronchoscopy with transbronchial biopsy.
• Be willing and able to sign the informed consent.

Exclusion Criteria

• Patients with known bleeding diathesis.
• Platelet count <50,000 per μL within 14 days of the biopsy procedure.
• Current use of systemic anticoagulation or antiplatelet therapy without the ability to hold therapy for the recommended amount of time prior to an invasive procedure. (aspirin monotherapy is acceptable)
• Inability or unwillingness to give informed consent or study procedures.
• Pregnant or nursing females, or females who intend to become pregnant.
• Females of child-bearing potential who decline a pregnancy test prior to enrollment.
• If an investigator does not feel that this study is in the subject’s best interest or would be a good fit for the study.
• International Normalized Ratio (INR) > 1.5.
• Do Not Resuscitate (DNR) status.
• Do Not Intubate (DNI) status.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/04/2024. Questions regarding updates should be directed to the study team contact.